Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sean Ormond

Interventional Pain Medicine Glendale, AZ Medical Doctor

NPI 1699118943 CMS profile 4222310

18205 N 51St Ave Ste 125, Glendale, AZ 85308

Open in the dashboard

General payments

$11,328

586 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sean Ormond of Glendale, AZ is reported in the CMS Open Payments database as having received $11,328 across 586 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,148 70
2024 General $2,046 89
2023 General $1,183 75
2022 General $1,780 107
2021 General $2,839 159
2020 General $1,033 59
2019 General $1,299 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sean Ormond
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Sean Ormond were reported at $1,148. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Sean Ormond Interventional Pain Medicine median Middle half National median
2019 $1,299 $684 $216–$2,079 $163
2020 $1,033 $382 $122–$1,109 $114
2021 $2,839 $552 $167–$1,554 $132
2022 $1,780 $605 $187–$1,924 $149
2023 $1,183 $671 $195–$1,915 $160
2024 $2,046 $684 $206–$1,837 $164
2025 $1,148 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $6,700 423 payments
  2. Boston Scientific Corporation $1,916 47 payments
  3. Medtronic, Inc. $543 23 payments
  4. Nalu Medical, Inc. $311 15 payments
  5. NuVasive, Inc. $204 3 payments
  6. Nevro Corp. $199 6 payments
  7. AbbVie, Inc. $124 7 payments
  8. Vertos Medical, Inc. $111 5 payments
  9. Spinefrontier, Inc. $106 1 payment
  10. IBSA Pharma Inc. $102 5 payments
  11. Other $1,014 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,807 582 payments
  2. Travel and Lodging $499 3 payments
  3. Education $21 1 payment
Products named General payments · program years 2019–2025
  1. Proclaim IPG $2,279 126 payments
  2. PROCLAIM Neuromodulation $1,431 120 payments
  3. Proclaim Family of SCS IPGs $1,037 59 payments
  4. SPECTRA WAVEWRITER $989 7 payments
  5. ETERNA $605 36 payments
  6. Nalu Neurostimulation System $311 15 payments
  7. PROCLAIM Neuromodulation $301 20 payments
  8. KYPHON EXPRESS II KYPHOPAK TRAY $249 9 payments
  9. PROCLAIM Structural Heart $241 15 payments
  10. GENERAL PAIN MANAGEMENT $206 10 payments
  11. Other $3,585 180 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

866

Median for Interventional Pain Management: 1,220

Drug cost

$40,694

Median for Interventional Pain Management: $39,344

Branded share of claims

27.8%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Botox Onabotulinumtoxina Brand 14 $18,104
Belbuca Buprenorphine Hcl Brand 16 $7,742
Buprenorphine Generic 12 $3,433
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 119 $2,440
Oxycodone Hcl Generic 128 $1,936
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 73 $1,417
Pregabalin Generic 35 $799
Naloxone Hcl Generic 15 $794
Gabapentin Generic 76 $738
Tizanidine Hcl Generic 68 $617

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$320,193

Of which drugs: $4,169

Medicare patients

249

Average age 71

Services billed

11,820

126 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Depression 32%
Ischemic heart disease 29%
Chronic kidney disease 27%
Diabetes 19%
Osteoporosis 18%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 72 573 $417
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 126 2,227 $191
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 122 542 $151
Injection, ketorolac tromethamine, per 15 mg J1885 Office 55 265 $123
Injection, midazolam hydrochloride, per 1 mg J2250 Office 75 334 $35

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ROXYBOND
  • PROTEGA PHARMACEUTIALS LLC $41
$41 — —
QULIPTA
  • AbbVie, Inc. $25
$25 — —
NURTEC ODT
  • PFIZER INC. $18
$18 — —
ZAVZPRET
  • PFIZER INC. $18
$18 — —
UBRELVY
  • AbbVie, Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

586 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record